Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02556268 · ClinicalTrials.gov registry record · Phase 1
Interaction With HIV Antiretroviral Agents
A Phase 1 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT02556268 is a Phase 1 study that has completed, run by Bayer. The registered enrollment target is 40 participants.
The verdict
NCT02556268, a Phase 1 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
To investigate the pharmacokinetic drug-drug interaction potential of fixed dose antiretroviral therapies, i.e. ATRIPLA, COMPLERA, STRIBILD, TRIUMEQ, or any approved antiretroviral protease inhibitor in combination with (preferably) TRIUMEQ, on the exposure to riociguat in HIV patients on a stable dose of one of these therapies. • To Assess the safety and tolerability of riociguat treatment in combination with these fixed-dose antiretroviral therapies.
Interventions
- DRUG Riociguat (Adempas, BAY 63-2521)
- DRUG ATRIPLA
- DRUG COMPLERA
- DRUG STRIBILD
- DRUG TRIUMEQ
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2016-02-23 |
| Est. Completion | 2016-12-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02556268
The ClinicalTrials.gov registry entry for NCT02556268 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Riociguat (Adempas, BAY 63-2521) is the first listed.
NCT02556268 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02556268 about?
NCT02556268 is a clinical study titled "Interaction With HIV Antiretroviral Agents". To investigate the pharmacokinetic drug-drug interaction potential of fixed dose antiretroviral therapies, i.e. ATRIPLA, COMPLERA, STRIBILD, TRIUMEQ, or any approved antiretroviral protease inhibitor in combination with (preferably) TRIUMEQ, on the exposure to riociguat in HIV patients on a stable d...
What is the current status of trial NCT02556268?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2016-02-23. Estimated completion is 2016-12-07.
What interventions are being tested in trial NCT02556268?
The interventions under investigation include: Riociguat (Adempas, BAY 63-2521) (DRUG), ATRIPLA (DRUG), COMPLERA (DRUG), STRIBILD (DRUG), TRIUMEQ (DRUG).
Who is sponsoring clinical trial NCT02556268?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.